Regenerative IOH Injection Enters Phase II With No Precedent and High Filler Bar

FDA Clears Lynch Regenerative Medicine's rhPDGF-BB for Phase II IOH Trial

The US Food and Drug Administration (FDA) has authorized Lynch Regenerative Medicine’s investigational new drug (IND) application for a Phase II study of injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB). This trial aims to treat adults with infraorbital hollowing (IOH), a condition characterized by skin thinning and tissue loss below the eyes. The randomized, multi-centre, dose-ranging study will assess the tolerability, safety, and early efficacy of rhPDGF-BB injection. Primary endpoints include safety outcomes and changes on the Canfield Infraorbital Hollowing Scale at 12 weeks, with secondary endpoints evaluating tissue quality, pharmacokinetics, and immunogenicity.

• Lynch Regenerative Medicine has achieved a significant regulatory and clinical development milestone with the FDA's authorization of its IND application. This clearance allows the company to advance rhPDGF-BB into a Phase II study for infraorbital hollowing, underscoring progress in its regenerative medicine pipeline.
• The upcoming Phase II trial for rhPDGF-BB is designed as a randomised, multi-centre, dose-ranging study. Its primary objectives are to evaluate the tolerability, safety, and early efficacy of the injection, with key primary endpoints focusing on safety and changes measured by the Canfield Infraorbital Hollowing Scale at 12 weeks.
• Lynch Regenerative Medicine is committed to biologic approaches that promote the regeneration of a patient's own tissue, positioning rhPDGF-BB as a potentially superior alternative to traditional fillers. This trial represents a rigorous scientific evaluation of their pure PDGF platform's potential in aesthetic regenerative medicine applications.

Addressing the Unmet Need in Infraorbital Hollowing

Current approaches for infraorbital hollowing include Juvéderm Voluma XC filler, autologous fat-based grafting, and lower blepharoplasty with ligament or fat manipulation. Across these modalities, benefits are tempered by need for retreatment, procedure-specific adverse events, and variable durability and aesthetic gain.

• Retreatment burden and persistent filler effects: 18 patients (18%) required additional treatment within 3 months, with average time until additional treatment of 35.7 days. Patients administered SVF-gel to restore volume in the periorbital region had a reoperation rate of 12.7% [6/47] vs. 34.2% [13/38] for nanofat+high-density fat after 3 to 8 months. In patients with history of HA filler undergoing lower blepharoplasty, 83.3% showed evidence of ≥1 filler-associated adverse effect, hyaluronidase for dissolution of filler was often indicated, and 43.8% experienced prolonged post-operative oedema requiring further intervention and follow-up.

• Safety and morbidity profile: With Juvéderm Voluma XC, adverse effects included bruising (in 10 [10%]), contour irregularities (2 [2%]), swelling (3 [3%]), and Tyndall effect (1 [1%]), with hyaluronidase required in 3 patients (3%). For autologous fat grafting to eyelids and periorbital area, frequent complications were edema, chemosis, and contour irregularity, with an overall complication rate of 7.9% (95% CI, 4.8%-12.8%), while fat necrosis, oil cysts and lipogranuloma typically presented as firm, painless nodules or oil cysts weeks to months post-procedure. Surgical adjuncts carried chemosis in four patients (13%) and scleral show requiring operative correction in one patient (3 percent), and orbicularis retaining ligament release was associated with postoperative swelling and chemosis of significantly longer duration and a higher likelihood of developing postoperative ectropion.

• Uncertain incremental benefit and outcome variability: There were no significant differences in overall aesthetic result, change in steatoblepharon or tear trough deformity, and postoperative ecchymosis in patients who had orbicularis retaining ligament release compared with those who did not. In comparison of deep nasolabial fat lift with lower blepharoplasty with fat transposition, duration of swelling (P < 0.001) was significantly longer and incidence of chemosis (P = 0.024) was significantly higher in the MRDN group, with transient retraction higher in the LBF group whereas cicatricial ectropion was higher in the MRDN group. Independent photographic review success rate for helium plasma RF was 53% at day 90 and 33% at day 180 largely due to challenges with photographic consistency.

Evaluating rhPDGF-BB's Safety and Efficacy in IOH

Key trials in infraorbital hollowing and tear trough rejuvenation span surgical, injectable, and topical approaches, with heterogeneous designs ranging from retrospective single-surgeon series to prospective cohorts and small comparative studies. Endpoints consistently combine clinician-graded morphometric or aesthetic scales with patient-reported satisfaction and safety assessments.

The Established Role of rhPDGF-BB in Regenerative Medicine

Recombinant human platelet-derived growth factor-BB (rhPDGF-BB) is considered an important component for periodontal wound healing and a key element in the periodontal regeneration triad. Randomized controlled clinical trials have demonstrated that purified recombinant human platelet-derived growth factor-BB (rhPDGF-BB) in combination with bone graft materials is effective in treating intrabony periodontal defects.

• Severe periodontal intrabony defects as the trialled indication: assessment focused on combining rhPDGF-BB with xenogeneic bone substitutes to treat severe intrabony periodontal defects, including challenging deep and wide intrabony defects in three patients treated using a combination of rhPDGF-BB and xenogeneic graft matrix.

• Combination graft protocol and observation period: treatment used rhPDGF-BB in combination with xenogeneic bone substitutes with probing depth (PD) reduction, bleeding on probing (BOP), mobility reduction, and radiographic bone fill (RBF) observed for 12 to 18 months.

• Reported clinical and radiographic outcomes: PD decreased from 9 mm to 4 mm, BOP was eliminated, mobility decreased, and RBF ranged from 85% to 95% over the postsurgical observation period, indicating that combination of rhPDGF-BB with xenogeneic bone substitutes is a safe and effective graft that leads to favorable clinical and radiographic outcomes. Intervention models for these trials were not detailed in the retrieved material. The knowledge base does not have sufficient information on this aspect.

Beyond Fillers: A Regenerative Approach to Under-Eye Rejuvenation

The FDA's green light for a Phase II study of injectable recombinant human platelet-derived growth factor-BB (rhPDGF-BB) for infraorbital hollowing (IOH) signals an exciting, potentially transformative direction for aesthetic medicine. Currently, the landscape for treating under-eye concerns, characterized by volume loss and skin thinning, is largely dominated by hyaluronic acid (HA) dermal fillers. While effective for immediate volumetric correction, these fillers primarily mask the issue rather than addressing the underlying tissue degradation.

rhPDGF-BB, however, represents a fundamentally different approach. Platelet-derived growth factors are well-established regulators of cell growth, viability, and migration, playing a crucial role in tissue regeneration and the synthesis of extracellular matrix components like collagen. By directly stimulating these biological processes, rhPDGF-BB aims to actively restore tissue quality and volume, moving beyond temporary filling to genuine biological rejuvenation. This could offer patients more durable and natural-looking outcomes, potentially setting a new standard for how age-related tissue loss is managed in aesthetics.

However, the path forward is not without its complexities. The very mechanisms that make PDGF a powerful regenerative agent also present significant risks. Research consistently highlights PDGF's involvement in promoting excessive collagen deposition and fibrotic remodeling in various organs, from the heart to the liver, and in conditions like uterine fibroids. Therefore, a critical challenge for the Phase II dose-ranging study will be to identify a therapeutic window that stimulates beneficial tissue regeneration without triggering undesirable fibrosis or tissue overgrowth in the delicate infraorbital region. Furthermore, as an injectable recombinant protein, rhPDGF-BB carries the inherent risk of immunogenicity and localized injection site reactions, which are particularly sensitive considerations in an aesthetic product. The study's focus on safety, tolerability, and early efficacy, alongside detailed assessments of tissue quality and immunogenicity, will be paramount in determining if this promising regenerative strategy can safely and effectively carve out a new niche in the competitive aesthetic market.